论文部分内容阅读
目的评价含克力芝的抗病毒治疗(ART)方案,与中国常规一线治疗方案在CD4~+T淋巴细胞(简称CD4细胞)计数≥350个/μL的初治、成人艾滋病病毒(HIV)感染者和艾滋病(AIDS)病人中的治疗效果及终止治疗情况。方法采用回顾性研究的方法,选择云南省2012年入组、既往未服用过抗病毒治疗药物、且基线CD4细胞≥350个/μL的成人病人作为观察对象。以初始治疗含克力芝的方案为基准,按照感染途径、性别和治疗医院相同,年龄相差不超过5岁与使用非克力芝方案的病人(对照组)进行1:1匹配后,克立芝组和非克立芝组各256例病人,观察两组在治疗效果及终止治疗方面的差异。结果在观察周期内,两组的治疗效果在每一个观察阶段差异均无统计学意义。克力芝组和非克力芝组治疗第1年的病毒载量抑制率分别为92.0%、92.9%,第2年为94.3%、91.2%,第3年为96.8%、97.2%,第4年为94.2%、95.1%;治疗第1年末,克力芝组CD4细胞增加数量为161.5(47~328)个/μL,高于非克力芝组的增加数量115(4~230)个/μL,(z=3.2,P=0.001)。随访至第4年,两组CD4细胞增加数量差异无统计学意义(z=0.52,P=0.61)。治疗的终止主要发生在第一年内,之后逐渐趋于平稳。观察的0.5年内,非克力芝组在治比例低于克力芝组(χ~2=4.00,P=0.04),其他各观察时点上两组的在治比例差异均无统计学意义。结论在云南省常规的抗病毒治疗管理模式下,在早期初治的成人病人中均能获得较理想的病毒控制效果,但使用含克力芝的治疗方案能在治疗第一年内更好地帮助病人增加CD4细胞,终止治疗的比例低于非克力芝组。
Objective To evaluate the antimicrobial therapy of Aricea chinensis (ART) and compare with the naïve and adult human immunodeficiency virus (HIV) infection in which CD4 + T lymphocytes (CD4 cells) counts ≥350 cells / μL for routine first-line treatment in China. And AIDS patients in the treatment effect and termination of treatment. Methods A retrospective study was conducted to select adult patients who had not been treated with antiviral drugs in Yunnan Province in 2012 and whose baseline CD4 cells were ≥ 350 cells / μL. Based on the initial treatment of Crematorhizobium, according to the route of infection, the same sex and treatment hospital, the age difference of not more than 5 years old patients with non-gram force program (control group) 1: 1 match, 256 patients in Zhizu and Fulizhi group, respectively, to observe the difference between the two groups in the treatment effect and the termination of treatment. Results During the observation period, there was no significant difference in the therapeutic effect between the two groups during each observation period. The inhibition rates of viral load in the first and second year of curcumin and febaizhi group were 92.0% and 92.9% respectively, 94.3% and 91.2% in the second year, 96.8% and 97.2% in the third year, respectively (94.2%) and 95.1% (95.1%) respectively. At the end of the first year of treatment, the number of CD4 cells increased from 161.5 (47 to 328) / μL in the Kelixi group to 115 (4-30) μL, (z = 3.2, P = 0.001). At the fourth year of follow-up, there was no significant difference in the number of CD4 cells between the two groups (z = 0.52, P = 0.61). The termination of treatment occurred mainly within the first year and then gradually stabilized. During the 0.5 years of observation, there was no significant difference in the rate of cure between the two groups at other points of observation when the proportion of non-gram force Chi group was lower than that of Kelixi group (χ ~ 2 = 4.00, P = 0.04). Conclusions Under the conventional antiviral treatment and management model in Yunnan Province, the ideal virus control effect can be obtained in the early-onset adult patients, but the treatment with gliquidin can better help in the first year of treatment Patient increased CD4 cells, the proportion of termination of treatment was lower than non-grams of force Chi group.